These effects, along with a past report demonstrating that a little-molecule ACKR3 agonist CCX771 reveals anxiolytic-like behavior in mice,two support the idea of targeting ACKR3 as a novel way to modulate the opioid program, which could open new therapeutic avenues for opioid-connected Conditions.Disclaimer: The above is really a sponsored post, t